Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABFRA:7AL0 Debt-to-Equity is 0.79 as of Mar. 2026, which is 888% above its 10-year median of 0.08. The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Alligator Bioscience AB ranks worse than 83.42% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alligator Bioscience AB's Debt-to-Equity or its related term are showing as below:
FRA:7AL0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.02 Med: 0.08 Max: 6.29
Current: 0.78
During the past 12 years, the highest Debt-to-Equity Ratio of Alligator Bioscience AB was 6.29. The lowest was -4.02. And the median was 0.08.
FRA:7AL0's Debt-to-Equity is ranked worse than 83.42% of 959
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:7AL0: 0.78
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Alligator Bioscience AB Debt-to-Equity Related Terms
Alligator Bioscience AB Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7AL0 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (FRA:7AL0) has a Debt-to-Equity of 0.79 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alligator Bioscience AB and its competitors. This is 888% above median its historical median of 0.08. According to the industry distribution chart, Alligator Bioscience AB ranks #800 out of 959 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Alligator Bioscience AB's Debt-to-Equity too high?
Alligator Bioscience AB's current Debt-to-Equity of 0.79 is 888% above median its 10-year median of 0.08. The Biotechnology industry median Debt-to-Equity is 0.15. Alligator Bioscience AB's value of 0.79 is 426.7% above this industry median. Based on the distribution chart, Alligator Bioscience AB ranks #800 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Alligator Bioscience AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #800 out of 959 companies for Debt-to-Equity. This places Alligator Bioscience AB in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Alligator Bioscience AB's value of 0.79 is 426.7% above this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.15, Alligator Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alligator Bioscience AB's current Debt-to-Equity of 0.79 is 426.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Debt-to-Equity is 0.79, which is 888% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Debt-to-Equity of 0.79. The current Debt-to-Equity is 0.79, which is 888% above median its 10-year median of 0.08 and 426.7% above the Biotechnology industry median of 0.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Debt-to-Equity is 0.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AL0 has been successfully added to your 
